Male doctor comforting female patient in consulting room

Obesity Treatment

CONTACT US

Packaging solutions for GLP-1 obesity chronic disease treatment

With a broad portfolio of drug containment and drug delivery solutions, SCHOTT Pharma ensures that pharmaceutical companies can focus on drug development while we take care of drug-container interaction, shelf life, and easy administration. 
With a long-standing track record and a dedication to keep even the most delicate molecules, such as GLP-1 RA peptides and GLP-1-based drug innovations, safe during filling, storage, and administration, SCHOTT Pharma is your reliable partner for effective obesity management solutions.

Challenge

Global demand is rising

Since 1997, the World Health Organization (WHO) has recognized obesity as a chronic disease, followed by the American Medical Association in 2013 and the European Commission in 20211. Affecting around 650 million people worldwide2, obesity is a chronic disease that can be treated with GLP-1 drugs. They can lower the blood sugar levels of patients and control the secretion of glucagon, which increases the blood sugar. Modern drugs based on GLP-1 RA (Glucagon-like Peptide-1 Receptor Agonist) can also curb hunger and promote slower eating.

As the global demand for GLP-1-based obesity drugs rises, a reliable container supply, smooth operations, and safe and easy self-administration become crucial.

At SCHOTT Pharma, our commitment is to deliver advanced drug containment and drug delivery solutions for obesity, ensuring the safe storage and precise administration of GLP-1-based drugs. Our primary objective is to support our valued customers in meeting the growing global demand for these pharmaceuticals.
 

Sources
1European Commission classifies obesity as a chronic disease - The Lancet Diabetes & Endocrinology
2WHO Obesity and overweight
a person is sitting on the edge of a bed, checking their blood sugar levels with a glucose meter
Product solution

The ideal container for your GLP-1-based obesity drug

Innovative GLP-1-based drugs undergo continuous improvement. While GLP-1 RA drugs have been in the market for quite a while, new and more effective molecules are now being developed. They all have one thing in common: they consist of tiny molecules that need to be stored safely from the point of filling until administration. At SCHOTT Pharma, we are proud to cover a broad range of potential packaging solutions based on your needs.
Regulatory

The easy way through the regulatory registration process

After choosing your ideal drug containment or drug delivery solution, SCHOTT Pharma supports you throughout your regulatory registration process. We take care your selected product has regulatory availability in all countries where you intend to go to market. Different countries follow different registration processes, we will prepare you and your product to meet compliance with the respective international norms and standards, as well as country-specific laws and guidelines. 

Man and woman discuss a document in an office
Compatibility

A commitment to compatibility

At SCHOTT Pharma, we prioritize patient convenience and accessibility. Our drug delivery solutions are designed with compatibility in mind, ensuring they work seamlessly with a wide range of injection devices. Whether you use off-the-shelf pen injectors, auto injectors, or similar devices, our containers are engineered to facilitate easy and precise drug administration.

We understand the importance of ensuring that patients can confidently and comfortably self-administer their medications, and our commitment to compatibility reflects our dedication to enhancing the overall patient experience.
Fill-and-finish

Smooth fill-and-finish operations

At SCHOTT Pharma, we recognize the importance of efficient fill-and-finish operations for our customers. We offer containment solutions that are designed for ease and efficiency, minimizing downtime and drug waste. 

Additionally, we closely collaborate with the leading fill-and-finish machine vendors to ensure smooth operational processes. With options for both standard bulk filling and ready-to-use filling, we provide flexibility to optimize your pharmaceutical production while maintaining the highest standards of quality and efficiency.
SCH-P_Stoppering-Illustration_Website_Desktop-950x594_20240220.png

Improved fill-and-finish processes reduce total cost of ownership

In this whitepaper, we discuss how RTU packaging can reduce TCO, increase flexibility, improve time to market, and lower reject costs. Published in the March 2023 issue of European Pharmaceutical Manufacturer.

Illustration of whitepaper Improved fill-and-finish processes reduce total cost of ownership

*Field is required

I agree that SCHOTT Pharma AG & Co. KGaA may send me e-mails with information on products and services of SCHOTT Pharma. My data will not be passed on to third parties. After registration, I can revoke my consent at any time at the SCHOTT Subscription Center following the link in each email footer.

Our online portals provide us with an anonymous measurement of web traffic, which enables us to better understand our visitors and to improve the web experience and our content continuously. By submitting the form, you consent that we connect this data to you personally to maximize your user experience and to help our customer service team interact with you in an efficient manner. The data collected includes information on what pages you visited, how often and how long you visited our websites, which content you viewed during those visits.

Sustainability

Sustainable solutions for large-scale drug manufacturing and packaging

When it comes to large quantities, the question of sustainable drug containment solutions and proper waste management arises. SCHOTT Pharma is committed to  integrating environmental approaches in our product and service solutions, and is ready to support customers in managing sustainability compliance within their supply chain. This includes: 

  • Services to facilitate customer reviews of SCHOTT Pharma’s sustainability performance and assessment of the product carbon footprint (PCF).
  • A sustainable procurement program using the third-party rating platform EcoVadis, providing quick and easy access to standardized information about our sustainability performance.
  • Product-specific carbon footprint assessment projects to promote the collaborative understanding of the emission contributions of your containment solution.

SCHOTT Pharma Containers made out of FIOLAX® Pro glass tubing – a pharmaceutical glass to be produced in an electric melting tank. This switch in glass melting technology plus the usage of green electricity can save e.g. up to 50% CO2 emissions of a 10ml vial.

Exterior view of SCHOTT Pharma’s headquarters

Get in touch

Florence Buscke

Florence Buscke

Head of Global Product Management Bulk & Sterile

*Field is required

SCHOTT Pharma will use your data only for reacting to your inquiry. Find more information about processing your personal data in SCHOTT Pharma’s data privacy policy

 

I agree that SCHOTT Pharma AG & Co. KGaA may send me e-mails with information on products and services of SCHOTT Pharma. My data will not be passed on to third parties. After registration, I can revoke my consent at any time at the SCHOTT Subscription Center following the link in each email footer.

Register for the latest news

Stay up-to-date with information about SCHOTT Pharma service. Register for our newsletter and get scientific knowledge through whitepaper, articles, and new online training.

I agree that SCHOTT Pharma AG & Co. KGaA may send me e-mails with information on products and services of SCHOTT Pharma. My data will not be passed on to third parties. After registration, I can revoke my consent at any time at the SCHOTT Subscription Center following the link in each email footer.